newsfilter
← Latest News
GlobeNewswire·

AEON Biopharma Reports Second Quarter 2026 Financial Results and Provides Corporate Update

  • AEON Biopharma executed a $15.3 million financing with milestone warrants providing potential for an additional $34.0 million in gross proceeds to support ABP-450 development
  • Upfront proceeds from the July 2026 offering provide cash runway into the first quarter of 2027
  • The company completed a Biosimilar Biological Product Development Type 2a meeting with the FDA in Q1 2026, receiving feedback on its analytical similarity strategy
  • A BPD Type 2b interaction with the FDA is expected in the second half of 2026 to inform clinical pharmacology and comparative clinical study requirements
  • NYSE American listing compliance was restored on August 3, 2026, after resolving previously identified deficiencies
  • ABP-450 demonstrated identical primary amino acid sequences to BOTOX with 93.5%–99.3% peptide sequence coverage as presented at AAN and AHS meetings
  • Cash and cash equivalents totaled $3.4 million as of June 30, 2026, excluding $13.6 million in net proceeds from the July 2026 public offering
  • The company reported a net loss of $12.948 million for the six months ended June 30, 2026
  • Total operating expenses reached $11.851 million for the six months ended June 30, 2026, with research and development costs at $4.973 million
  • ABP-450 is a biosimilar to BOTOX targeting the U.S. therapeutic neurotoxin market, manufactured by Daewoong Pharmaceutical in an FDA-authorized facility
  • AEON holds exclusive development and distribution rights for ABP-450 in the United States, Canada, the European Union, the United Kingdom, and other international territories